ERAS
ERAS
NASDAQ · Biotechnology

Erasca Inc

$15.99
+1.32 (+9.00%)
Financial Highlights (FY 2025)
Revenue
897.62M
Net Income
-100,463,137
Gross Margin
65.2%
Profit Margin
-11.2%
Rev Growth
+16.3%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 65.2% 65.2% 65.2%
Operating Margin -9.3% -11.3% -9.0%
Profit Margin -11.2% -10.4% -13.9%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 897.62M 918.48M 827.43M
Gross Profit 585.04M 598.63M 539.29M
Operating Income -83,221,783 -103,638,723 -74,827,445
Net Income -100,463,137 -95,918,574 -115,001,691
Gross Margin 65.2% 65.2% 65.2%
Operating Margin -9.3% -11.3% -9.0%
Profit Margin -11.2% -10.4% -13.9%
Rev Growth +16.3% +1.8% +8.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 487.48M 423.83M 373.12M
Total Equity 1.97B 1.68B 1.92B
D/E Ratio 0.25 0.25 0.19
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -104,291,949 -115,509,109 -110,721,792
Free Cash Flow -130,963,293 -137,514,931 -125,568,165